RU2003136151A - 2, 5-диарилпиразины, 2, 5-диарилпиридины и 2, 5-диарилпиримидины в качестве модуляторов рецептора кортикотропин-рилизинг-фактора 1 (крф1) - Google Patents

2, 5-диарилпиразины, 2, 5-диарилпиридины и 2, 5-диарилпиримидины в качестве модуляторов рецептора кортикотропин-рилизинг-фактора 1 (крф1) Download PDF

Info

Publication number
RU2003136151A
RU2003136151A RU2003136151/04A RU2003136151A RU2003136151A RU 2003136151 A RU2003136151 A RU 2003136151A RU 2003136151/04 A RU2003136151/04 A RU 2003136151/04A RU 2003136151 A RU2003136151 A RU 2003136151A RU 2003136151 A RU2003136151 A RU 2003136151A
Authority
RU
Russia
Prior art keywords
alkyl
phenyl
alkoxy
amino
mono
Prior art date
Application number
RU2003136151/04A
Other languages
English (en)
Russian (ru)
Inventor
Кь нхуэй ХУЭНГ (US)
Кьянхуэй ХУЭНГ
Кевин ХОДЖЕТТС (US)
Кевин Ходжеттс
Дарио ДОЛЛЕР (US)
Дарио Доллер
Пинг ДЖИ (US)
Пинг Джи
Ясучика ЯМАГУЧИ (US)
Ясучика ЯМАГУЧИ
Original Assignee
Ньюроджин Корпорейшн (US)
Ньюроджин Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюроджин Корпорейшн (US), Ньюроджин Корпорейшн filed Critical Ньюроджин Корпорейшн (US)
Publication of RU2003136151A publication Critical patent/RU2003136151A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2003136151/04A 2001-06-12 2002-05-22 2, 5-диарилпиразины, 2, 5-диарилпиридины и 2, 5-диарилпиримидины в качестве модуляторов рецептора кортикотропин-рилизинг-фактора 1 (крф1) RU2003136151A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29748301P 2001-06-12 2001-06-12
US60/297,483 2001-06-12

Publications (1)

Publication Number Publication Date
RU2003136151A true RU2003136151A (ru) 2005-05-20

Family

ID=23146501

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003136151/04A RU2003136151A (ru) 2001-06-12 2002-05-22 2, 5-диарилпиразины, 2, 5-диарилпиридины и 2, 5-диарилпиримидины в качестве модуляторов рецептора кортикотропин-рилизинг-фактора 1 (крф1)

Country Status (16)

Country Link
US (2) US6887875B2 (https=)
EP (1) EP1399428A1 (https=)
JP (1) JP2005500286A (https=)
AP (1) AP2003002924A0 (https=)
BG (1) BG108427A (https=)
CA (1) CA2450262A1 (https=)
EC (1) ECSP034898A (https=)
HR (1) HRP20031096A2 (https=)
HU (1) HUP0400179A3 (https=)
IL (1) IL159058A0 (https=)
IS (1) IS7060A (https=)
MX (1) MXPA03011391A (https=)
PL (1) PL367476A1 (https=)
RU (1) RU2003136151A (https=)
TN (1) TNSN03133A1 (https=)
WO (1) WO2002100838A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233949A2 (en) * 2000-03-16 2002-08-28 Neurogen Corporation 5-substituted arylpyrimidines
JP2005533014A (ja) * 2002-04-26 2005-11-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換ピラジン誘導体
ATE325115T1 (de) 2002-08-19 2006-06-15 Glaxo Group Ltd Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
EP1565454A1 (en) * 2002-11-21 2005-08-24 Pharmacia & Upjohn Company LLC Pyrazine compounds as crf modulators
AU2004295050A1 (en) 2003-11-24 2005-06-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
WO2006005571A1 (de) * 2004-07-14 2006-01-19 Basf Aktiengesellschaft 2-substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
AU2006275403A1 (en) * 2005-08-02 2007-02-08 Lexicon Pharmaceuticals, Inc. 2-aminoaryl pyridines as protein kinases inhibitors
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
US7932256B2 (en) * 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
EP2493871B1 (en) * 2009-10-30 2014-09-03 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9351494B2 (en) 2013-05-03 2016-05-31 Inscent, Inc. Honeybee repellents and uses thereof
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
CN103788367B (zh) * 2014-02-26 2017-01-11 中国科学院长春应用化学研究所 一种聚酯酰胺及其制备方法
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
JP2022074173A (ja) * 2019-03-18 2022-05-18 住友化学株式会社 ２，５－ジクロロピラジンの製造方法
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用
CN113429354A (zh) * 2021-07-22 2021-09-24 广东嘉博制药有限公司 一种盐酸甲氧明聚合物杂质及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1458118A (fr) * 1964-02-26 1966-03-04 Ciba Geigy Nouveaux amino-phényl-alcanols et procédé pour leur préparation
US3660404A (en) * 1969-02-24 1972-05-02 Du Pont U.v.-absorbing ortho-hydroxyphenyl substituted bipyrimidyls
DE2064380C3 (de) * 1970-12-30 1981-01-22 Hoechst Ag, 6000 Frankfurt Lichtempfindliches Gemisch
JPS625970A (ja) 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
DE68926635T2 (de) * 1988-04-25 1997-01-02 Dainippon Ink & Chemicals 2,5-Disubstituierte Pyrazin-Derivate, Pyrimidin-Derivate und sie enthaltende Flüssigkristalle
JPH02209873A (ja) * 1989-02-08 1990-08-21 Dainippon Ink & Chem Inc 光学活性２，５―ジ置換ピリミジン誘導体
JP2770385B2 (ja) * 1989-03-16 1998-07-02 セイコーエプソン株式会社 ピリミジン誘導体
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
JPH0948760A (ja) * 1995-08-03 1997-02-18 Dainippon Ink & Chem Inc ピリミジン化合物
JP4044175B2 (ja) * 1996-07-26 2008-02-06 株式会社半導体エネルギー研究所 光学活性化合物及び該化合物を含有する反強誘電性液晶組成物
US6686486B1 (en) * 1997-05-07 2004-02-03 Padma Marwah Process for effecting allylic oxidation
SE9702651D0 (sv) * 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
ID24959A (id) * 1998-01-28 2000-08-31 Shionogi & Co Senyawa-senyawa trisiklik yang baru
CO5210940A1 (es) * 1999-05-04 2002-10-30 Novartis Ag Compuestos plaguicidas derivados de pirimidina y composiciones que los contienen
PL365238A1 (en) * 2000-02-16 2004-12-27 Neurogen Corporation Substituted arylpyrazines

Also Published As

Publication number Publication date
CA2450262A1 (en) 2002-12-19
TNSN03133A1 (en) 2005-12-23
HRP20031096A2 (en) 2005-08-31
MXPA03011391A (es) 2004-07-01
US20030119844A1 (en) 2003-06-26
IL159058A0 (en) 2004-05-12
PL367476A1 (en) 2005-02-21
HUP0400179A2 (hu) 2004-08-30
IS7060A (is) 2003-11-28
EP1399428A1 (en) 2004-03-24
ECSP034898A (es) 2004-01-28
WO2002100838A1 (en) 2002-12-19
JP2005500286A (ja) 2005-01-06
HUP0400179A3 (en) 2004-10-28
US6887875B2 (en) 2005-05-03
BG108427A (bg) 2005-01-31
US20050176721A1 (en) 2005-08-11
AP2003002924A0 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
RU2003136151A (ru) 2, 5-диарилпиразины, 2, 5-диарилпиридины и 2, 5-диарилпиримидины в качестве модуляторов рецептора кортикотропин-рилизинг-фактора 1 (крф1)
Choi et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
US8614222B2 (en) Methods of preventing and treating low bone mass diseases
US8957093B2 (en) N-biphenylmethylindole modulators of PPARG
CA2432870A1 (en) Substituted triazole diamine derivatives as kinase inhibitors
Nishiu et al. JTP‐426467 acts as a selective antagonist for peroxisome proliferator‐activated receptor γin vitro and in vivo
JP2005500286A5 (https=)
JP2007527909A (ja) イオンチャンネルモジュレーター
US20230114241A1 (en) Methods of treating epilepsy using the same
HUP0202399A2 (hu) Dopamin D3 receptor ligandumok alkalmazása veseelégtelenség kezelésére szolgáló gyógyszerek előállítására
US20240009169A9 (en) PPARG Modulators for the Treatment of Osteoporosis
WO2004080943A1 (ja) シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
Zhang et al. Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents
EP2636414A1 (en) Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
US8815883B2 (en) Compounds and methods for inhibiting serotonin synthesis
JP2010509402A5 (https=)
JP2004515449A (ja) 第６ｇタンパク質共役型受容体の小分子調節物質
US20250084056A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
US20080139628A1 (en) Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists
US9040713B2 (en) Methods of managing blood sugar levels and compositions related thereto
JP2000500490A (ja) 糖尿病治療用の４−ヒドロキシクマリン−３−カルボキシアミド
JP2006151810A (ja) ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤
US9150521B2 (en) Methods of preventing and treating diabetes by inhibiting serotonin synthesis
Lehner et al. Evidence that the multiflorine‐derived substituted quinazolidine 55P0251 augments insulin secretion and lowers blood glucose via antagonism at α2‐adrenoceptors in mice
WO2022255346A1 (ja) ミトコンドリア超複合体の形成促進剤、筋力維持又は増進用組成物、及び筋機能低下若しくはミトコンドリア機能低下疾患の治療又は予防用医薬組成物、並びにミトコンドリアの超複合体の形成に関与する物質のスクリーニング方法

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20050712